Hydrolysis and Inhibition Profiles of Beta-lactamases from Molecular Classes A to D with Doripenem, Imipenem, and Meropenem

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2009 Nov 4

PMID 19884379

Citations 55

Authors

Anne Marie Queenan

Wenchi Shang

Robert Flamm

Karen Bush

Affiliations

Soon will be listed here.

Abstract

The stability of doripenem to hydrolysis by beta-lactamases from molecular classes A to D was compared to the stability for imipenem and meropenem. Doripenem was stable to hydrolysis by extended-spectrum beta-lactamases and AmpC type beta-lactamases and demonstrated high affinity for the AmpC enzymes. For the serine carbapenemases SME-3 and KPC-2 and metallo-beta-lactamases IMP-1 and VIM-2, doripenem hydrolysis was generally 2- to 150-fold slower than imipenem hydrolysis. SPM-1 hydrolyzed meropenem and doripenem fourfold faster than imipenem.

Citing Articles

Cefepime-taniborbactam and ceftibuten-ledaborbactam maintain activity against KPC variants that lead to ceftazidime-avibactam resistance.

Myers C, Stevenson A, Miller B, Daigle D, Uehara T, Pevear D Antimicrob Agents Chemother. 2025; 69(3):e0151124.

PMID: 39927783 PMC: 11881561. DOI: 10.1128/aac.01511-24.

Dynamical responses predict a distal site that modulates activity in an antibiotic resistance enzyme.

Beer M, Oliveira A, Tooke C, Hinchliffe P, Tsz Yan Li A, Balega B Chem Sci. 2024; .

PMID: 39364073 PMC: 11443494. DOI: 10.1039/d4sc03295k.

Enhancing the antibacterial efficacy of vancomycin analogues: targeting metallo-β-lactamases and cell wall biosynthesis.

Sarkar P, Xu W, Vazquez-Hernandez M, Dhanda G, Tripathi S, Basak D Chem Sci. 2024; .

PMID: 39309102 PMC: 11409854. DOI: 10.1039/d4sc03577a.

Electric Fields Are a Key Determinant of Carbapenemase Activity in Class A β-Lactamases.

Jabeen H, Beer M, Spencer J, van der Kamp M, Bunzel H, Mulholland A ACS Catal. 2024; 14(9):7166-7172.

PMID: 38721371 PMC: 11075022. DOI: 10.1021/acscatal.3c05302.

Vaborbactam increases meropenem susceptibility in clinical isolates displaying MexXY and AmpC upregulation.

Castanheira M, Doyle T, Hubler C, DeVries S, Shortridge D mSphere. 2023; 8(5):e0016223.

PMID: 37768064 PMC: 10597463. DOI: 10.1128/msphere.00162-23.

References

Queenan A, Shang W, Kania M, Page M, Bush K . Interactions of ceftobiprole with beta-lactamases from molecular classes A to D. Antimicrob Agents Chemother. 2007; 51(9):3089-95. PMC: 2043179. DOI: 10.1128/AAC.00218-07. View

Lolans K, Queenan A, Bush K, Sahud A, Quinn J . First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States. Antimicrob Agents Chemother. 2005; 49(8):3538-40. PMC: 1196250. DOI: 10.1128/AAC.49.8.3538-3540.2005. View

Mushtaq S, Ge Y, Livermore D . Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases. Antimicrob Agents Chemother. 2004; 48(4):1313-9. PMC: 375315. DOI: 10.1128/AAC.48.4.1313-1319.2004. View

Soge O, Queenan A, Ojo K, Adeniyi B, Roberts M . CTX-M-15 extended-spectrum (beta)-lactamase from Nigerian Klebsiella pneumoniae. J Antimicrob Chemother. 2005; 57(1):24-30. DOI: 10.1093/jac/dki429. View

Mushtaq S, Ge Y, Livermore D . Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother. 2004; 48(8):3086-92. PMC: 478525. DOI: 10.1128/AAC.48.8.3086-3092.2004. View

Walsh T . Clinically significant carbapenemases: an update. Curr Opin Infect Dis. 2008; 21(4):367-71. DOI: 10.1097/QCO.0b013e328303670b. View

Sykes R, Bonner D, Bush K, Georgopapadakou N . Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria. Antimicrob Agents Chemother. 1982; 21(1):85-92. PMC: 181833. DOI: 10.1128/AAC.21.1.85. View

Murphy T, Simm A, Toleman M, Jones R, Walsh T . Biochemical characterization of the acquired metallo-beta-lactamase SPM-1 from Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2003; 47(2):582-7. PMC: 151762. DOI: 10.1128/AAC.47.2.582-587.2003. View

Ge Y, Wikler M, Sahm D, Blosser-Middleton R, Karlowsky J . In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother. 2004; 48(4):1384-96. PMC: 375337. DOI: 10.1128/AAC.48.4.1384-1396.2004. View

10.

Bauernfeind A, Stemplinger I, Jungwirth R, Giamarellou H . Characterization of the plasmidic beta-lactamase CMY-2, which is responsible for cephamycin resistance. Antimicrob Agents Chemother. 1996; 40(1):221-4. PMC: 163087. DOI: 10.1128/AAC.40.1.221. View

11.

Bush K, Jacoby G, Medeiros A . A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 1995; 39(6):1211-33. PMC: 162717. DOI: 10.1128/AAC.39.6.1211. View

12.

LEDENT P, Raquet X, Joris B, Van Beeumen J, Frere J . A comparative study of class-D beta-lactamases. Biochem J. 1993; 292 ( Pt 2):555-62. PMC: 1134246. DOI: 10.1042/bj2920555. View

13.

Bush K, Freudenberger J, Sykes R . Interaction of azthreonam and related monobactams with beta-lactamases from gram-negative bacteria. Antimicrob Agents Chemother. 1982; 22(3):414-20. PMC: 183759. DOI: 10.1128/AAC.22.3.414. View

14.

Queenan A, Shang W, Schreckenberger P, Lolans K, Bush K, Quinn J . SME-3, a novel member of the Serratia marcescens SME family of carbapenem-hydrolyzing beta-lactamases. Antimicrob Agents Chemother. 2006; 50(10):3485-7. PMC: 1610102. DOI: 10.1128/AAC.00363-06. View

15.

Walther-Rasmussen J, Hoiby N . OXA-type carbapenemases. J Antimicrob Chemother. 2006; 57(3):373-83. DOI: 10.1093/jac/dki482. View

16.

Bush K, Tanaka S, Bonner D, Sykes R . Resistance caused by decreased penetration of beta-lactam antibiotics into Enterobacter cloacae. Antimicrob Agents Chemother. 1985; 27(4):555-60. PMC: 180094. DOI: 10.1128/AAC.27.4.555. View

17.

Cheng Y, Prusoff W . Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973; 22(23):3099-108. DOI: 10.1016/0006-2952(73)90196-2. View

18.

Yigit H, Queenan A, Rasheed J, Biddle J, Domenech-Sanchez A, Alberti S . Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing beta-lactamase KPC-2. Antimicrob Agents Chemother. 2003; 47(12):3881-9. PMC: 296202. DOI: 10.1128/AAC.47.12.3881-3889.2003. View

19.

LARAKI N, Franceschini N, Rossolini G, Santucci P, Meunier C, De Pauw E . Biochemical characterization of the Pseudomonas aeruginosa 101/1477 metallo-beta-lactamase IMP-1 produced by Escherichia coli. Antimicrob Agents Chemother. 1999; 43(4):902-6. PMC: 89223. DOI: 10.1128/AAC.43.4.902. View

20.

Pillar C, Torres M, Brown N, Shah D, Sahm D . In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob Agents Chemother. 2008; 52(12):4388-99. PMC: 2592858. DOI: 10.1128/AAC.00381-08. View